Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

Melanoma Research

Volumn 12, Issue 2, 2002, Pages 175-178

  Paul, M J ^a   Summers, Y ^a   Calvert, A H ^a   Rustin, G ^a   Brampton, M H ^a   Thatcher, N ^a   Middleton, M R ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Brain metastasis; Dacarbazine; Melanoma; Relapse; Temozolomide

Indexed keywords

DACARBAZINE; TEMOZOLOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFECT; HUMAN; MELANOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; DACARBAZINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036246203     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200204000-00011     Document Type: Article

References (18)

1. Melanoma: Chemotherapy
2. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
3. A randomised phase III trial of dacarbazine, BCNU, cisplatin and tamoxifen versus dacarbazine and interferon in advanced melanoma
4. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α
5. Sequential chemoimmunotherapy in the treatment of metastatic melanoma
6. Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen
7. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy
8. A randomized, phase III study of temozolomide (TMZ) versus dacarbazine (DTIC) in the treatment of patients with advanced, metastatic malignant melanoma
9. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials
10. 11C-temozolomide uptake by human recurrent high grade astrocytomas
11. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high grade glioma
12. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma
13. Pharmacologic studies of the anti-tumor agent 5-(dimethyltriazeno)-imidazole-4-carboxamide
14. 6-Methylguanine-DNA methyltransferase in pretreatment tumor biopsies as a predictor of response to temozolomide in melanoma
15. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4-hourly schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study
16. Prospective randomized trial of the treatment of metastatic melanoma patients using chemotherapy with cisplatin, dacarbazine and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
17. Phase III randomised trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL-2) and interferon-alpha-2b (INF) versus CVD in patients (pts) with metastatic melanoma